The Wall Street Journal: Federal Trade Commission to consider tougher line on pharmaceutical mergers

18237500 - businessman hand pointing to investment as concept

WASHINGTON — The Federal Trade Commission on Tuesday announced plans to reconsider its approach to scrutinizing pharmaceutical mergers, with an eye toward taking a more aggressive stance against drug-company deals that may harm competition.

The initiative, spurred by the FTC’s acting Democratic chairwoman, Rebecca Kelly Slaughter, signals what could be a tougher road ahead for the industry during the Biden administration.

“Given the high volume of pharmaceutical mergers in recent years, amid skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry, it is imperative that we rethink our approach toward pharmaceutical merger review,” Ms. Slaughter said.

The FTC is starting a working group that will take a broader look at how pharmaceutical deals affect the marketplace. Other participants include the Justice Department’s antitrust division, state attorneys general and competition officials from Canada, the U.K. and Europe, the FTC said.

An expanded version of this article appears on

Popular articles from

: GoPro revamps video-editing app to lure customers that don’t own its cameras

Previous article

In One Chart: For the first time in over a year COVID-19 isn’t the No. 1 ‘tail risk’ for investors, in Bank of America’s view

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News